je.st
news
Tag: hepatitis
CEO Frazier: Merck is eager for deals, sees strong prospects for drugs for cancer, hepatitis C
2016-01-05 22:22:53| Biotech - Topix.net
Merck's chief executive says the drugmaker is "raring to go" on deals this year, particularly for small and midsize acquisitions of companies or their experimental drugs. CEO Kenneth Frazier, speaking Tuesday at a Goldman Sachs conference of CEOs of health care companies in Boston, also said he expects more approvals and growing sales from new cancer drug Keytruda.
Tags: strong
deals
cancer
drugs
Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
2015-12-18 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the companys marketing authorization application (MAA) for elbasvir/grazoprevir (50mg/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
marketing
update
agency
BIO Issues Statement on Hepatitis C medicines report.
2015-12-07 14:31:08| Industrial Newsroom - All News for Today
In his statement regarding report released by Senators Grassley and Wyden, BIO Senior VP of Communications Kenneth Lisaius stated that BIO is reviewing said report in full and generally does not comment on product pricing by member companies. Lisaius added, however, that "balanced debate about the cost of groundbreaking cures" cannot narrow their focus on price but also acknowledge value provided to patients as well as overall healthcare system.
Tags: report
issues
statement
bio
Senate investigation: Maker of breakthrough drug for hepatitis C sought to maximize revenue
2015-12-01 18:05:31| Biotech - Topix.net
The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, Senate investigators said Tuesday. A bipartisan report from the Senate Finance Committee concluded that California-based Gilead Sciences was focused on maximizing revenue even as the company's own analysis showed a lower price would allow more patients to be treated.
Tags: to
drug
investigation
revenue
Real life Dallas Buyers Club operation helps hepatitis C patients with free drugs
2015-11-30 13:55:15| Biotech - Topix.net
A Dallas Buyers Club- style operation that helps hepatitis C patients get lifesaving drugs at knockdown prices plans to go a step further for World Aids Day on Tuesday - free drugs for those who can least afford them. Nearly a quarter of a million Australians carry hepatitis C, a "viral time bomb" that kills half a million people worldwide each year, according to the World Health Organisation.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »